This bill requires the Food and Drug Administration (FDA) to report to Congress on barriers to the domestic manufacturing of imported active pharmaceutical ingredients, finished drug products, and devices that are critical to public health.
The report must recommend strategies to overcome such barriers. The FDA may, to the extent appropriate, implement the strategies.
| Action Date | Type | Text | Source |
|---|---|---|---|
| 2022-02-14 | Committee | Referred to the Subcommittee on Health. | House committee actions |
| 2022-02-11 | IntroReferral | Referred to the House Committee on Energy and Commerce. | House floor actions |
| 2022-02-11 | IntroReferral | Introduced in House | Library of Congress |